Nicotinamide riboside tartrate (0.5 nM; 24 hours) reduces the acetylation status of Ndufa9 and SOD2[1]. Nicotinamide riboside tartrate increases intracellular and mitochondrial NAD + content in C2C12, Hepa1.6, and HEK293 cells in a concentration-dependent manner at concentrations ranging from 1-1000 μM[1]. Nicotinamide riboside tartrate boosts NAD to restore antiviral poly(ADP-ribose) polymerase (PARP) functions to support innate immunity for coronavirus (CoVs), a cause of COVID-19[3]. Western Blot Analysis[1]Cell Line: HEK293T cells Concentration: 0.5 nM Incubation Time: 24 hours Result: Reduced the acetylation status of Ndufa9 and SOD2.

Chronic Nicotinamide riboside tartrate (p.o.; 400 mg/kg/day; for 16 weeks) supplementation increases plasma and intracellular NAD + content in a tissue-specific manner[1]. Animal Model: 10-week-old C57Bl/6J mice[1]Dosage: 400 mg/kg Administration: PO; daily; for 16 weeks Result: Increased plasma and intracellular NAD + content in a tissue-specific manner.